Related Experiment Video

Updated: May 28, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Treatment advances have not improved the early death rate in acute promyelocytic leukemia

James Scott McClellan1, Holbrook E Kohrt, Steven Coutre

  • 1Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305-5821, USA.

Haematologica
|October 14, 2011
PubMed

Insights

Early death in acute promyelocytic leukemia (APL) is higher than previously thought, contributing significantly to treatment failure. This finding highlights a critical challenge in managing this curable leukemia.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Acute promyelocytic leukemia (APL) is generally considered highly curable.
  • Early mortality in APL clinical trials is typically reported below 10%.

Purpose of the Study:

  • To investigate the incidence and clinical features of early mortality in APL patients treated at Stanford Hospital.
  • To compare institutional findings with national data.

Main Methods:

  • Retrospective analysis of 70 APL patients treated at Stanford Hospital since March 1997.
  • Analysis of the Surveillance, Epidemiology and End Results (SEER) Database (1977-2007).

Main Results:

  • 19% and 26% of Stanford APL patients died within 7 and 30 days of admission, respectively.
  • SEER data showed an average 30-day APL mortality of 20% from 1977-2007, with no significant improvement over time.
  • Early death emerged as the primary cause of treatment failure in APL.

Conclusions:

  • Early mortality in APL is higher than previously reported in clinical trials.
  • National data confirms a persistent high rate of early death in APL.
  • Reducing early mortality is crucial for improving treatment outcomes in APL.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...